-
3 weeks ago | 
plasticsurgerypractice.com | Alyx Arnett
Healthcare company Organon announced results from an analysis of its Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA (tapinarof) cream, 1% once daily for treatment in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema. The findings demonstrate that AD disease activity remained mild in patients who had achieved treatment success and subsequently entered a treatment-free interval lasting on average 80 days.
-
3 weeks ago | 
24x7mag.com | Alyx Arnett
Olympus Corp has launched the ScopeLocker Air endoscope drying cabinet, offering a new drying option for healthcare facilities. Drying endoscope channels is a critical component of reprocessing. The ScopeLocker Air endoscope drying cabinet, manufactured by Capsa Healthcare and distributed by Olympus Corp, helps facilitate the drying process and is designed to meet society guidelines for endoscope drying and storage.
-
3 weeks ago | 
plasticsurgerypractice.com | Alyx Arnett
Health Canada has approved the use of Radiesse, a biostimulatory dermal filler, for the treatment of moderate wrinkles in the décolleté area. The regulatory milestone expands the product's approved uses in Canada beyond the face and hands. Radiesse, developed by Merz Aesthetics, is designed to stimulate the body's natural collagen and elastin production.
-
3 weeks ago | 
24x7mag.com | Alyx Arnett
Cardinal Health has launched its multi-parameter, single-patient use vital signs monitoring cable and lead wire system, the Kendall DL Multi System, in the United States. The system enables continuous monitoring of cardiac activity, blood oxygen level, and temperature through one point of connection.
-
3 weeks ago | 
24x7mag.com | Alyx Arnett
A contractor working at the construction site of a new University of Iowa hospital in North Liberty has been accused of stealing more than $60,000 worth of medical supplies and equipment, as well as construction equipment, and attempting to resell it online, according to WHO 13 Des Moines.
-
3 weeks ago | 
plasticsurgerypractice.com | Alyx Arnett
Rion Aesthetics announced that the US Food and Drug Administration (FDA) has allowed an Investigational New Drug (IND) application to proceed for a phase 1 investigator-initiated trial evaluating Purified Exosome Product (PEP) injected into the dermis. The study is sponsored and independently conducted by Clinical Testing Center of Beverly Hills and is being led by John H. Joseph, MD, a double board-certified facial plastic surgeon based in California.
-
3 weeks ago | 
24x7mag.com | Alyx Arnett
Medtronic and its subsidiary, Covidien, are recalling the Shiley adult flexible tracheostomy tube with TaperGuard cuff reusable inner cannula as the tube may become dislodged or move out of place if the securement flange becomes disconnected, according to a medical device recall notification from the US Food and Drug Administration. This could prevent patient breathing and/or block the airway, which may lead to a serious or life-threatening emergency.
-
3 weeks ago | 
24x7mag.com | Alyx Arnett
Baxter has issued a letter to affected customers recommending Novum IQ large volume pumps to be corrected prior to use due to a potential for underinfusion, according to a medical device recall notice from the US Food and Drug Administration (FDA). The correction is recommended if the device has been powered off with the administration set loaded, or after the “standby mode” feature has been activated.
-
3 weeks ago | 
24x7mag.com | Alyx Arnett
A new 2025 Future Ready Healthcare Survey Report from Wolters Kluwer Health, conducted in partnership with the independent marketing research firm Ipsos, reveals that while healthcare professionals widely recognize the transformative potential of generative AI (GenAI), most organizations are not yet ready to harness its full value.
-
3 weeks ago | 
24x7mag.com | Alyx Arnett
BiVACOR, a clinical-stage medical device company developing a titanium Total Artificial Heart, announced that its device has received Breakthrough Device Designation from the US Food and Drug Administration (FDA). The designation supports the BiVACOR Total Artificial Heart as a bridge to transplant for adults with severe biventricular or univentricular heart failure where current treatments, including LVADs, are not viable.
